Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Looking at options history for Vertex Pharmaceuticals VRTX we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential. The investment bank said it believes Vertex (VRTX) has “best in sector ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the price target to $361.00 from $376.00. Whitney Ijem has ...